Evidence map›Paper›PMID 20482770›Full record

ArticleBMC public health2010

Attributable mortality to radon exposure in Galicia, Spain. Is it necessary to act in the face of this health problem?

Mónica Pérez-Ríos, Juan M Barros-Dios, Agustín Montes-Martínez, Alberto Ruano-Ravina

Abstract read
In one paragraph

Article in BMC public health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Lung cancer mortality attributable to residential radon: a systematic scoping review.Journal of exposure science & environmental epidemiology · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mónica Pérez-RíosDepartment of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Juan M Barros-Dios
Agustín Montes-Martínez
Alberto Ruano-Ravina

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadon is the second risk factor for lung cancer after tobacco consumption and therefore it is necessary to know the burden of disease due to its exposure. The objective of this study is to estimate radon-attributable lung cancer mortality in Galicia, a high emission area located at the Northwest Spain.

methodsA prevalence-based attribution method was applied. Prevalence of tobacco use and radon exposure were obtained from a previously published study of the same area. Attributable mortality was calculated for each of six possible risk categories, based on radon exposure and smoking status. Two scenarios were used, with 37 Bq/m3 and 148 Bq/m3 as the respective radon exposure thresholds. As the observed mortality we used lung cancer mortality for 2001 from the Galician mortality registry.

resultsMortality exclusively attributable to radon exposure ranged from 3% to 5% for both exposure thresholds, respectively. Attributable mortality to combined exposure to radon and smoking stood at around 22% for exposures above 148 Bq/m3. Applying the United States Environmental Protection Agency (EPA) action level, radon has a role in 25% of all lung cancers.

conclusionsAlthough the estimates have been derived from a study with a relatively limited sample size, these results highlight the importance of radon exposure as a cause of lung cancer and its effect in terms of disease burden. Radon mitigation activities in the study area must therefore be enforced.

Indexed as

AgedEnvironmental ExposureFemaleHumansLung NeoplasmsMaleMiddle AgedMortalityNeoplasms, Radiation-InducedPrevalenceRadonSmokingSpainRadon

Identifiers

PMID20482770
PMCPMC2885334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.